Certara is the leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development.
PRINCETON, NJ – Oct. 24, 2018 – Certara today announced that Craig Rayner, PharmD, MBA, senior vice president, integrated drug development with Certara Strategic Consulting, has been awarded the 2018 Distinguished Alumni Award for the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University.
October 15, 2018 – Certara today announced that it has formed a strategic collaboration with Hedera Hashgraph. Synchrogenix®, Certara’s regulatory sciences division, has been building distributed applications in the life sciences and healthcare markets that will expand its reach in the areas of transparency and disclosure, regulatory reporting and data sharing, and collaboration/communications from drug development through market access.
PRINCETON, NJ – Oct. 9, 2018 – Certara today announced that the US Food and Drug Administration (FDA) has renewed, and in many cases increased, its number of Certara software licenses for reviewing new drug and biologics applications.
PRINCETON, NJ – Oct. 5, 2018 – Certara today announced that it is participating in 40 sessions at the ninth American Conference on Pharmacometrics (ACoP9).
PRINCETON, NJ – Sept. 26, 2018 – Certara announced today the launch of its BaseCase Portal cloud-based platform, that allows for the rapid creation of fully-customizable mobile apps that connect live to mathematical models and algorithms, and help HCPs optimize treatment for individual patients.
PRINCETON, NJ – Sept. 13, 2018 – Certara announced today that it has acquired Pirana, a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
August 16, 2018 – Certara today announced the launch of D360 v10.5, the first in a series of releases focused on delivering biologic-relevant tools together with D360’s data access capabilities.
PRINCETON, NJ – Aug. 2, 2018 – Certara today reported that 95% of novel new drug approvals by the US Food and Drug Administration (FDA) in the first half of 2018 were supported by Certara software or services. Those results emphasize how much modeling and simulation has become an integral part of regulatory submissions and highlight Certara’s leadership role in the field.
PRINCETON, NJ – July 26, 2018 – Certara announced today that Clinical Pharmacology & Therapeutics has published its “Letter to the Editor” describing the important role that quantitative systems pharmacology can play in defining dosing criteria for first-in-human clinical trials, together with the European Medicines Agency’s response.
PRINCETON, NJ – June 14, 2018 – Certara was privileged to participate as a key member of the Medicines Development for Global Health development team to achieve FDA approval of moxidectin.